DOCSLIB.ORG

Non-Interventional (Ni) Study Protocol Pass

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Non-Interventional (Ni) Study Protocol Pass XALKORI (crizotinib) A8081038, A Multinational Active Safety Surveillance Study of Crizotinib in Europe Final Protocol Amendment 2, 19 Febuary 2015 NON-INTERVENTIONAL (NI) STUDY PROTOCOL PASS Information Title A multinational active safety surveillance study of crizotinib in Europe and the United States Protocol number A8081038 Protocol version identifier Final (version 1.2) Date of last version of protocol 19 Febuary 2015 EU Post Authorisation Study (PAS) ENCEPP/SDPP/8097 register number Active substance L01XE16/Crizotinib Medicinal product XALKORI Product reference EU/1/12/793/001-004 Product number EMEA/H/C/002489 Marketing Authorisation Holder (MAH) Pfizer Limited Joint PASS No Research question and objectives The objective of this study is to evaluate the safety and effectiveness of crizotinib among lung cancer patients in the real world setting in Europe and the United States. Countries of study Denmark, Finland, Sweden, the Netherlands and the United States Author Kui Huang, PhD, MPH Pfizer Inc 235 East 42nd Street New York, NY 10017 090177e18627024f\Approved\Approved On: 25-Feb-2015 14:49 Pfizer Confidential Page 1 of 63 XALKORI (crizotinib) A8081038, A Multinational Active Safety Surveillance Study of Crizotinib in Europe Final Protocol Amendment 2, 19 Febuary 2015 Marketing Authorisation Holder(s) Marketing Authorisation Holder(s) Pfizer Limited Ramsgate Road, Sandwich, Kent CT130NJ United Kingdom MAH contact person Kui Huang, PhD, MPH Pfizer Inc 235 East 42nd Street New York, NY 10017 This document contains confidential information belonging to Pfizer. Except as otherwise agreed to in writing, by accepting or reviewing this document, you agree to hold this information in confidence and not copy or disclose it to others (except where required by applicable law) or use it for unauthorized purposes. In the event of any actual or suspected breach of this obligation, Pfizer must be promptly notified. 090177e18627024f\Approved\Approved On: 25-Feb-2015 14:49 Pfizer Confidential Page 2 of 63 XALKORI (crizotinib) A8081038, A Multinational Active Safety Surveillance Study of Crizotinib in Europe Final Protocol Amendment 2, 19 Febuary 2015 1. TABLE OF CONTENTS 1. TABLE OF CONTENTS.......................................................................................................3 LIST OF TABLES.....................................................................................................................4 LIST OF FIGURES ...................................................................................................................5 APPENDICES ...........................................................................................................................5 2. LIST OF ABBREVIATIONS................................................................................................6 3. RESPONSIBLE PARTIES....................................................................................................7 4. ABSTRACT...........................................................................................................................8 5. AMENDMENTS AND UPDATES.....................................................................................10 6. MILESTONES.....................................................................................................................11 7. RATIONALE AND BACKGROUND................................................................................12 8. RESEARCH QUESTION AND OBJECTIVES .................................................................15 8.1. Objectives................................................................................................................15 8.1.1. Primary Objective.......................................................................................15 8.1.2. Secondary Objectives .................................................................................15 9. RESEARCH METHODS ....................................................................................................16 9.1. Study Design ...........................................................................................................16 9.2. Setting......................................................................................................................16 9.2.1. Inclusion Criteria ........................................................................................16 9.2.2. Exclusion Criteria .......................................................................................17 9.3. Variables..................................................................................................................17 9.4. Data Sources............................................................................................................18 9.4.1. Sources of Population-Based Data .............................................................18 9.4.2. Adjudication and Validation of Primary Endpoints from Population- Based Health Care Data Sources .....................................................................19 9.5. Study Procedures.....................................................................................................21 9.6. Study Size................................................................................................................23 9.6.1. Estimated Number of ALK-Positive NSCLC Patients Receiving Crizotinib Treatment........................................................................................24 9.6.2. Estimated Number of NSCLC Patients Likely Treated with Ceritinib, Erlotinib or Gefitinib........................................................................................25 9.6.3. Precision Calculations ................................................................................26 090177e18627024f\Approved\Approved On: 25-Feb-2015 14:49 9.7. Data Management ...................................................................................................27 Pfizer Confidential Page 3 of 63 XALKORI (crizotinib) A8081038, A Multinational Active Safety Surveillance Study of Crizotinib in Europe Final Protocol Amendment 2, 19 Febuary 2015 9.7.1. Data Management.......................................................................................27 9.7.1.1. Data Linkage .............................................................................27 9.7.1.2. Data Cleaning............................................................................27 9.8. Data Analysis ..........................................................................................................27 9.8.1. Interim Report.............................................................................................30 9.9. Quality Control........................................................................................................30 9.10. Limitations of the Research Methods....................................................................31 9.11. Other Aspects ........................................................................................................32 10. PROTECTION OF HUMAN SUBJECTS ........................................................................32 10.1. Patient Information and Consent...........................................................................32 10.2. Patient Withdrawal................................................................................................32 10.3. Institutional Review Board (IRB)/Independent Ethics Committee (IEC) ............32 10.4. Ethical Conduct of the Study ................................................................................32 11. MANAGEMENT AND REPORTING OF ADVERSE EVENTS/ADVERSE REACTIONS ......................................................................................................................32 12. PLANS FOR DISSEMINATING AND COMMUNICATING STUDY RESULTS........33 13. REFERENCES ..................................................................................................................34 LIST OF TABLES Table 1. Variables, Roles, Data Sources and Operational Definitions ...............................17 Table 2. Estimated Numbers of ALK-Positive NSCLC Patients Likely Treated with Crizotinib in an approximately 3-year Database Study in Sweden, Denmark, the Netherlands, Finland, and the US ..................................................24 Table 3. Estimated Numbers of NSCLC Patients Likely Treated with Erlotinib or Gefitinib in an approximately 3-Year Study using Existing Data Sources in Sweden, Denmark, the Netherlands, Finland, and the US....................................25 Table 4. Precision Calculations for Different Incidence Proportions.................................26 090177e18627024f\Approved\Approved On: 25-Feb-2015 14:49 Pfizer Confidential Page 4 of 63 XALKORI (crizotinib) A8081038, A Multinational Active Safety Surveillance Study of Crizotinib in Europe Final Protocol Amendment 2, 19 Febuary 2015 LIST OF FIGURES Figure 1. Process of Validating Primary Endpoints.............................................................21 Figure 2. Study Data Abstraction.........................................................................................22 Figure 3. Study Duration by Country...................................................................................23 Figure 4. Study Timeline......................................................................................................23 APPENDICES Appendix 1. DATA SOURCES BY COUNTRY....................................................................35
Load more

Recommended publications
  • A Method for Constructing a New Extensible Nomenclature for Clinical Coding Practices in Sub-Saharan Africa
    MEDINFO 2017: Precision Healthcare through Informatics 965 A.V. Gundlapalli et al. (Eds.) © 2017 International Medical Informatics Association (IMIA) and IOS Press. This article is published online with Open Access by IOS Press and distributed under the terms of the Creative Commons Attribution Non-Commercial License 4.0 (CC BY-NC 4.0). doi:10.3233/978-1-61499-830-3-965 A Method for Constructing a New Extensible Nomenclature for Clinical Coding Practices in Sub-Saharan Africa Sven Van Laere, Marc Nyssen, Frank Verbeke Department of Public Health (GEWE), Research Group of Biostatistics and Medical Informatics (BISI), Vrije Universiteit Brussel (VUB), Laarbeeklaan 103, 1090 Brussels, Belgium Abstract The word nomenclature has to be used with care in the context Clinical coding is a requirement to provide valuable data for of sub-Saharan Africa. By the word “nomenclature”, usually billing, epidemiology and health care resource allocation. In they understand: “a coding system to provide codes that are sub-Saharan Africa, we observe a growing awareness of the used in invoices, to specify the health services that were pro- need for coding of clinical data, not only in health insurances, vided for particular patients”. We define nomenclature in a but also in governments and the hospitals. Presently, coding broader way, also taking into account the clinical definition of systems in sub-Saharan Africa are often used for billing pur- health services. poses. In this paper we consider the use of a nomenclature to In this paper we will present a way to build this new nomen- also have a clinical impact.
    [Show full text]
  • Description of Alternative Approaches to Measure and Place a Value on Hospital Products in Seven Oecd Countries
    OECD Health Working Papers No. 56 Description of Alternative Approaches to Measure Luca Lorenzoni, and Place a Value Mark Pearson on Hospital Products in Seven OECD Countries https://dx.doi.org/10.1787/5kgdt91bpq24-en Unclassified DELSA/HEA/WD/HWP(2011)2 Organisation de Coopération et de Développement Économiques Organisation for Economic Co-operation and Development 14-Apr-2011 ___________________________________________________________________________________________ _____________ English text only DIRECTORATE FOR EMPLOYMENT, LABOUR AND SOCIAL AFFAIRS HEALTH COMMITTEE Unclassified DELSA/HEA/WD/HWP(2011)2 Health Working Papers OECD HEALTH WORKING PAPERS NO. 56 DESCRIPTION OF ALTERNATIVE APPROACHES TO MEASURE AND PLACE A VALUE ON HOSPITAL PRODUCTS IN SEVEN OECD COUNTRIES Luca Lorenzoni and Mark Pearson JEL Classification: H51, I12, and I19 English text only JT03300281 Document complet disponible sur OLIS dans son format d'origine Complete document available on OLIS in its original format DELSA/HEA/WD/HWP(2011)2 DIRECTORATE FOR EMPLOYMENT, LABOUR AND SOCIAL AFFAIRS www.oecd.org/els OECD HEALTH WORKING PAPERS http://www.oecd.org/els/health/workingpapers This series is designed to make available to a wider readership health studies prepared for use within the OECD. Authorship is usually collective, but principal writers are named. The papers are generally available only in their original language – English or French – with a summary in the other. Comment on the series is welcome, and should be sent to the Directorate for Employment, Labour and Social Affairs, 2, rue André-Pascal, 75775 PARIS CEDEX 16, France. The opinions expressed and arguments employed here are the responsibility of the author(s) and do not necessarily reflect those of the OECD.
    [Show full text]
  • Federal Air Surgeon's
    Federal Air Surgeon’s Medical Bulletin Aviation Safety Through Aerospace Medicine 02-4 For FAA Aviation Medical Examiners, Office of Aerospace Medicine U.S. Department of Transportation Winter 2002 Personnel, Flight Standards Inspectors, and Other Aviation Professionals. Federal Aviation Administration Best Practices This article launches Best Practices, a new series of HEADS UP profiles highlighting the shared wisdom of the most A Dean Among Doctors senior of our senior aviation medical examiners. 2 Editorial: Research By Mark Grady Written by one of Dr. Moore’s pilot medical and Aviation Safety General Aviation News certification applicants, this article appeared in the November 22, 2002, issue of General Avia- 3 Certification Issues OCTOR W. DONALD MOORE of tion News. —Ed. and Answers Coats, N.C., knows a lot of pilots 6 Bariatric D— many quite intimately. After Surgery: all, as an Federal Administra- morning just to give medical exams for pilots in the area. How Long tion Aviation Administration- approved medical examiner, He estimates he’s given more to Wait? he’s poked and prodded quite than 12,000 flight physicals a few of them during his more over the past 41 years. 7 Checklist for than 40 years of making sure “I’ve given an average of Pilot they meet the FAA’s physical 300 flight physicals a year since Physical requirements for flying. 1960,” he says, noting those He also knows what it’s like exams have been in addition to fly, because he flew for 40 to running a busy general 8 Palinopsia Case years. medical and obstetrics Report Moore began giving FAA Dr.
    [Show full text]
  • Health & Coding Terminological Systems
    Health & Coding Terminological Systems Hamideh Sabbaghi, MS Ophthalmic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran Definition of Code Code is considered as word, letter, or number which has been used as passwords instead of words or phrases. Coding System 1. Classification system 2. Nomenclature system Classification System A well-known system of corrections for naming different stages of the disease. Nomenclature System A medical list of a specific system of preferred terms for naming disease. WHO- FIC • Main/reference classification • Related classifications to the main/ reference classification • Driven classification from the main/ reference classification Main/reference classification • ICD- 10 (1990, WHA) • ICD- 11 (2007, WHO) • http://who.int/classifications/apps/icd/icd10online/ ICD with a commonest usage can be used for: • Identification of health trend, mortality and morbidity statistics. • Clinical and health research purposes. Main/reference classification • ICD-9-CM (International Classification of Diseases, Ninth Revision, Clinical Modification) • ICF (International Classification of Function, Disability and Health) • ICHI (International Classification of Health Intervention) Related classifications to the main/ reference classification • ATC/DDD (The Anatomical Therapeutic chemical classification system with Defined Daily Doses) • ATCvet (The Anatomical Therapeutic Chemical Classification System for veterinary medicinal products) • ICECI (International Classification of External Causes
    [Show full text]
  • A Status Report, 2008-2009 WHO-FIC 2009/C006
    Seoul, Republic of Korea WHO-FIC Education Committee: WHO-FIC 2009/C006 10 - 16 October 2009 A Status Report, 2008-2009 Cassia Maria Buchalla and Marjorie S. Greenberg Co-chairs Abstract The WHO-FIC Education Committee (EC) was established at the 2003 WHO-FIC Network meeting in Cologne, Germany, as a successor to the Subgroup on Training and Credentialing of the WHO-FIC Implementation Committee. New terms of reference were developed at the Cologne meeting to reflect generic tasks for education and training on the International Statistical Classification of Diseases and Related Health Problems (ICD) and the International Classification of Functioning, Disability and Health (ICF). Specific tasks have been agreed for both ICD and ICF. The Education Committee (EC) assists and advises WHO in improving the quality of use of the WHO classifications in member states through the development of training and certification strategies, the identification of best training practices and by providing a network for sharing expertise and experiences on education and training. The principal ICD tasks relate to an international training and certification program for ICD-10 mortality and morbidity coders; this program has been developed in conjunction with the International Federation of Health Records Organizations (IFHRO), a non-governmental organization in official relations with WHO. A Joint WHO-FIC – IFHRO Collaboration (JC) was established in late 2004 to carry forward this work. The Education Committee’s ICF tasks are being carried out in collaboration with the WHO-FIC Network’s Functioning and Disability Reference Group (FDRG). The Education Committee held four teleconferences in 2009 and a mid-year meeting in Raleigh, North Carolina, USA, in cooperation with the Joint Collaboration.
    [Show full text]
  • The Impact of Systemic Inflammation on Brain Inflammation
    cover 28/6/04 12:58 PM Page 1 ISSN 1473-9348 Volume 4 Issue 3 July/August 2004 ACNR Advances in Clinical Neuroscience & Rehabilitation journal reviews • events • management topic • industry news • rehabilitation topic Review Articles: The Impact of Systemic Inflammation on Brain Inflammation; Genetics of Learning Disability Management Topic: Aneurysmal Subarachnoid Haemorrhage Rehabilitation Article: Progression and Correction of Deformities in Adults with Cerebral Palsy www.acnr.co.uk cover 28/6/04 12:58 PM Page 2 Leave gardening to the occasional, untrained volunteer Spend your hard-earned savings on a gardener Just do the gardening yourself Let your pride and joy turn into a jungle ® ropinirole PUT THEIR LIVES BACK IN THEIR HANDS cover 28/6/04 12:58 PM Page 3 REQUIP (ropinirole) Prescribing Information Editorial Board and contributors Presentation ‘ReQuip’ Tablets, PL 10592/0085-0089, each containing ropinirole hydrochloride equivalent to either 0.25, 0.5, 1, 2 or 5 mg Roger Barker is co-editor in chief of Advances in Clinical ropinirole. Starter Pack (105 tablets), £43.12. Follow On Pack (147 tablets), Neuroscience & Rehabilitation (ACNR), and is Honorary Consultant £80.00; 1 mg tablets – 84 tablets, £50.82; 2 mg tablets – 84 tablets, in Neurology at The Cambridge Centre for Brain Repair. He trained £101.64; 5 mg tablets – 84 tablets, £175.56. Indications Treatment of in neurology at Cambridge and at the National Hospital in London. idiopathic Parkinson’s disease. May be used alone (without L-dopa) or in His main area of research is into neurodegenerative and movement addition to L-dopa to control “on-off” fluctuations and permit a reduction in disorders, in particular parkinson's and Huntington's disease.
    [Show full text]
  • 2020 Lahiri Et Al Hallucinatory Palinopsia and Paroxysmal Oscillopsia
    cortex 124 (2020) 188e192 Available online at www.sciencedirect.com ScienceDirect Journal homepage: www.elsevier.com/locate/cortex Hallucinatory palinopsia and paroxysmal oscillopsia as initial manifestations of sporadic Creutzfeldt-Jakob disease: A case study Durjoy Lahiri a, Souvik Dubey a, Biman K. Ray a and Alfredo Ardila b,c,* a Bangur Institute of Neurosciences, IPGMER and SSKM Hospital, Kolkata, India b Sechenov University, Moscow, Russia c Albizu University, Miami, FL, USA article info abstract Article history: Background: Heidenhain variant of Cruetzfeldt Jacob Disease is a rare phenotype of the Received 4 August 2019 disease. Early and isolated visual symptoms characterize this particular variant of CJD. Reviewed 7 October 2019 Other typical symptoms pertaining to muti-axial neurological involvement usually appear Revised 9 October 2019 in following weeks to months. Commonly reported visual difficulties in Heidenhain variant Accepted 14 November 2019 are visual dimness, restricted field of vision, agnosias and spatial difficulties. We report Action editor Peter Garrard here a case of Heidenhain variant that presented with very unusual symptoms of pal- Published online 13 December 2019 inopsia and oscillopsia. Case presentation: A 62-year-old male patient presented with symptoms of prolonged af- Keywords: terimages following removal of visual stimulus. It was later on accompanied by intermit- Creutzfeldt Jacob disease tent sense of unstable visual scene. He underwent surgery in suspicion of cataratcogenous Heidenhain variant vision loss but with no improvement in symptoms. Additionally he developed symptoms of Oscillopsia cerebellar ataxia, cognitive decline and multifocal myoclonus in subsequent weeks. On the Palinopsia basis of suggestive MRI findings in brain, typical EEG changes and a positive result of 14-3-3 protein in CSF, he was eventually diagnosed as sCJD.
    [Show full text]
  • Unlocking the Mystery of Third Party Reimbursement in Kinesiotherapy
    Unlocking the Mystery of Third Party Reimbursement In Kinesiotherapy Provided by the American Kinesiotherapy Association Written by Joanne Byron, LPN, BSNH, CHA, CMC, CPC, MCMC, PCS Edited & Contributions made by Carl Byron, III, ATC-L, EMT-I, CHA, CPC, MCMC Health Care Consulting Services, Inc. PO Box 572 Medina, Ohio 44258-0572 www.hccsincorp.com Page 2 Table of Contents Page Introduction – Bridging the Gap between KT and Payor 3 Key Elements to Reimbursement 4 Provider Enrollment 5 State of Health Insurance 9 Medicare Benefit Policy Manual 10 Reimbursement Basics 12 Documentation 13 Appropriate Coding 14 Procedure Coding – a 2 Tier System 15 CPT Assistant 16 Diagnosis Code Assignment ICD-9-CM 21 ICD-10-CM 22 Understanding the Health Insurance Industry 26 Types of insurance and reimbursement methodology 26 Managed Care Contracting Considerations 30 Administrative Simplification 33 NCQA 37 Managed Care Terminology (terms & definitions from HHS) 38 Provided by the American Kinesiotherapy Association (AKTA) & Written by Health Care Consulting Services, Inc. (HCCS) Copyright © 2010 AKTA & HCCS, All Rights Reserved This document is not intended to provide legal or consulting advice. It is for educational purposes only. Please retain an attorney or consultant for specific information for your practice. Page 3 Introduction Bridging the gap between KT and payer “How do we get paid?” . A challenging question every health care provider faces, regardless of specialty and health insurance company. The purpose of this reimbursement manual is to provide a basic understanding of health care reimbursement and compliance prior to filing claims for Kinesiotherapy services. Physical medicine budgets are getting ever tighter, demands on rehab specialists’ time and skills are increasing.
    [Show full text]
  • Ata Lements for Mergency Epartment Ystems
    D ata E lements for E mergency D epartment S ystems Release 1.0 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES CDCCENTERS FOR DISEASE CONTROL AND PREVENTION D ata E lements for E mergency D epartment S ystems Release 1.0 National Center for Injury Prevention and Control Atlanta, Georgia 1997 Data Elements for Emergency Department Systems, Release 1.0 (DEEDS) is the result of contributions by participants in the National Workshop on Emergency Department Data, held January 23-25, 1996, in Atlanta, Georgia, subsequent review and comment by individuals who read Release 1.0 in draft form, and finalization by a multidisciplinary writing committee. DEEDS is a set of recommendations published by the National Center for Injury Prevention and Control of the Centers for Disease Control and Prevention: Centers for Disease Control and Prevention David Satcher, MD, PhD, Director National Center for Injury Prevention and Control Mark L. Rosenberg, MD, MPP, Director Division of Acute Care, Rehabilitation Research, and Disability Prevention Richard J. Waxweiler, PhD, Director Acute Care Team Daniel A. Pollock, MD, Leader Production services were provided by the staff of the Office of Communication Resources, National Center for Injury Prevention and Control, and the Management Analysis and Services Office: Editing Valerie R. Johnson Cover Design and Layout Barbara B. Lord Use of trade names is for identification only and does not constitute endorsement by the U.S. Department of Health and Human Services. This document and subsequent revisions can be found at the National Center for Injury Prevention and Control Web site: http://www.cdc.gov/ncipc/pub-res/deedspage.htm Suggested Citation: National Center for Injury Prevention and Control.
    [Show full text]
  • Understanding Remittance Advice
    Understanding the Remittance Advice: A Guide for Medicare Providers, Physicians, Suppliers, and Billers March 2006 DISCLAIMER This Guide was current at the time it was printed or downloaded. Medicare policy changes frequently so links to the source documents have been provided within the Guide for your reference. This Guide was prepared as a tool to assist providers and is not intended to grant rights or impose obligations. Although every reasonable effort has been made to assure the accuracy of the information within these pages, the ultimate responsibility for the correct submission of claims and response to any remittance advice lies with the provider of services. The Centers for Medicare & Medicaid Services (CMS) employees, agents, and staff make no representation, warranty, or guarantee that this compilation of Medicare information is error- free and will bear no responsibility or liability for the results or consequences of the use of this Guide. This publication is a general summary that explains certain aspects of the Medicare Program, but is not a legal document. The official Medicare Program provisions are contained in the relevant laws, regulations, and rulings. For ease of reading this Guide, the term “provider” is used generally to refer to providers of all Medicare Part A and Part B services, supplies, and equipment. When information specific to a particular provider type is presented, the name of the specific provider type is used [e.g., physician, supplier, hospital, Skilled Nursing Facility (SNF)]. Institutional providers refer to hospitals, SNFs, Home Health Agencies (HHAs), hospices, and other facility-based health care organizations that submit claims to Fiscal Intermediaries (FIs) and Regional Home Health Intermediaries (RHHIs).
    [Show full text]
  • Palinopsia in a Patient with a Left Pericalcarine Cavernous Haemangioma
    Case report Palinopsia in a patient with a left pericalcarine cavernous haemangioma Marco Curloa, Jovana Popovicb, Riccardo Pignattib, Leonardo Saccob a Rheinburg-Klinik AG, Walzenhausen, Switzerland b Neurocentre of Southern Switzerland, Ospedale Civico, Lugano, Switzerland Funding / potential competing interests: No financial support and no other potential conflict of interest relevant to this article were reported. Summary Case report Background: Palinopsia is the persistence of visual images after removal of We present the case of a 28-year-old man who experienced the exciting stimulus. It is commonly caused by occipital epileptic stati, focal an episode of acute cephalalgia in the left occipital region cerebral lesions, migraine. with no photophobia, phonophobia, osmophobia nor nau- Case: A 28-year-old man experienced two episodes of acute headache sea, but with a progressive loss of vision (an initially puncti- with negative scotoma and palinopsia. All symptoms recovered spontane- form scotoma spreading to the right part of visual field) and ously after one hour but palinopsia still persisted. The MRI showed a a peculiar visual symptom described as the persistence of c avernous haemangioma in the left occipital lobe and the EEG showed o bjects or anatomical details in the visual field lasting a few no sign of epileptic activity, but this data did not exclude an epilepsy. The minutes after looking away, referrable to palinopsia (for f luctuating manner and stereotypy of the symptom was, in fact, attributed e xample the patient kept on seeing the scalp of a friend he to an epileptic aetiology and palinopsia disappeared after initiation of anti- was talking to after looking away from him).
    [Show full text]
  • Report-Health Terminologies and Vocabularies Environmental Scan
    Health Terminologies and Vocabularies Environmental Scan Conducted for the National Committee on Vital and Health Statistics Subcommittee on Standards September 14, 2018 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Health Terminologies and Vocabularies Environmental Scan NCVHS Subcommittee on Standards This report was written by Susan L. Roy, MS, MLS, SNOMED CT Coordinator, and Vivian A. Auld, MLIS, Senior Specialist for Health Data Standards, both with the National Institutes of Health (NIH), National Library of Medicine, in collaboration with the NCVHS Standards Subcommittee: NCVHS Membership William W. Stead, MD, NCVHS Chair Nicholas L. Coussoule,* Subcommittee Co-chair Alexandra Goss,* Subcommittee Co-chair Bruce B. Cohen, PhD David A. Ross, ScD Debra Strickland, MS* Denise E. Love, BSN, MBA* Jacki Monson, JD Linda L. Kloss, MA, RHIA*, Terminology and Vocabulary Project Lead Llewellyn J. Cornelius, PhD Richard W. Landen, MPH, MBA* Robert L. Phillips, Jr., MD, MSPH Roland J. Thorpe, Jr., PhD Vickie M. Mays, PhD, MSPH *Member of the Subcommittee on Standards Rebecca Hines, MHS, NCVHS Executive Secretary/DFO Health Scientist National Center for Health Statistics, CDC, HHS Rashida Dorsey, PhD, MPH, NCVHS Executive Staff Director Director, Division of Data Policy Senior Advisor on Minority Health and Health Disparities Office of Science and Data Policy Office of the Assistant Secretary for Planning and Evaluation, HHS The National Committee on Vital and Health Statistics (NCVHS) serves as the advisory committee to the Secretary of Health and Human Services (HHS) on health data, statistics, privacy, national health information policy, and the Health Insurance Portability and Accountability Act (HIPAA) (42U.S.C.242k[k]).
    [Show full text]